BioPharma Dive 2023 Biotech Executive Outlooks

In a new BioPharma Dive panel hosted at this year’s J.P. Morgan Healthcare Conference, executives from ABIO-X, Ovid Therapeutics, and Lifemine Therapeutics spoke about their projections for the new year. Their outlook was somewhat tempered by the current down market and prospects of drug pricing reform, but they were at least somewhat optimistic.

According to Jacob Bell, “It’s possible that biotech and pharmaceutical companies will face even more uncertainty in the coming months, as they contend with more cautious venture capital backers, a public market that’s turned cold on the life sciences, and new legislation that gives the government unprecedented influence over drug pricing.”

To read more, click here.

(Source: BioPharma Dive, January 19^th, 2023)